| Document |
Document Title |
|
WO/2019/068772A1 |
The present invention relates to compounds of formula (I): wherein Q is selected from O or S; R1 is a saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include cyclic ...
|
|
WO/2019/070672A1 |
Bromine induced lactamization of vinyl acetohydroxamates facilitated syntheses of monocyclic β-lactams suitable for incorporation of a thiomethyl and extended functionality at the C(4) position. Elaboration of the resulting substituted ...
|
|
WO/2019/062848A1 |
The present invention discloses an N-(substituted sulfonyl)benzamide derivative, a preparation method therefor, and a pharmaceutical use thereof. Specifically, the present invention discloses an N-(substituted sulfonyl)benzamide derivati...
|
|
WO/2019/064184A1 |
The present application provides process for preparation of siponimod, intermediates of siponimod, salts of siponimod, polymorphic forms and solid dispersions of siponimod and its salts thereof. The present application specifically provi...
|
|
WO/2019/056123A1 |
Pharmaceutical compositions comprising one or more cannabinoids and a pharmaceutically acceptable carrier are disclosed. The compositions are in a form suitable for topical administration, and are useful in the treatment of pain. The can...
|
|
WO/2019/055509A1 |
N-(6-(((2R,3S)-3,4-dihydroxy butan-2-yl)oxy)-2-((4-fluoro benzyl)thio)pyrimidin-4-yl)-3-methylazetidine-1-sulfonamide (compound 4), a known chemokine modulator, in combination with colchicine is useful in the treatment of diseases/condit...
|
|
WO/2019/045035A1 |
The present invention relates to biaryloxy derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage ...
|
|
WO/2019/040106A2 |
The present disclosure relates to compounds according to Formulae disclosed herein, useful for treating diseases.
|
|
WO/2019/033219A1 |
A class of compounds useful in pharmaceutical compositions and methods for treating or preventing cancer is described. Analogs of Mycalolide B have been prepared and tested in breast and ovarian cancer cell lines. The compounds show util...
|
|
WO/2019/034702A1 |
The invention relates to compounds of Formula (I) and their use in therapy, for example in the treatment of mycobacterial infections or in the treatment of diseases caused by mycobacterium, such as tuberculosis
|
|
WO/2019/027055A1 |
Provided are nucleic-acid-containing lipid nanoparticles including a fatty acid ester analog of glycerol and a nucleic acid, which are not hydrolyzed by lipase.
|
|
WO/2019/023147A1 |
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured.The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, c...
|
|
WO/2019/023145A1 |
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured. The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, ...
|
|
WO/2018/144620A9 |
Provided herein are anti-fibrotic compounds, in particular those of Formula (I), that inhibit the TGF-beta signaling pathway. Also provided are pharmaceutical compositions comprising the anti-fibrotic compounds, and methods of treating d...
|
|
WO/2019/008507A1 |
The invention is directed to substituted azetidine derivatives. Specifically, the invention is directed to compounds according Formula I: (I) wherein C, D, L1,L2,L3,R1, R2, R4, R5, R6, z2, z4, z5, and z6are as defined herein; and salts t...
|
|
WO/2019/009412A1 |
The present invention addresses the problem of providing a novel compound having high LSD1 inhibitory activity, high selectivity for LSD1 inhibition, and/or having useful therapeutic effects for various diseases. One embodiment of the pr...
|
|
WO/2019/008025A1 |
The present invention relates to compounds of formula (I) wherein Q is selected from O or S; R1 is a non-aromatic heterocyclic group comprising at least one ring nitrogen atom, wherein R1 is attached to the sulfur atom of the sulfonylure...
|
|
WO/2018/185675A1 |
The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, R1, R2, R3, R4, L and m are as defined herein, which are active as modulators of retinoid-related orphan recept...
|
|
WO/2018/172251A1 |
The present invention relates to a compound of general formula (I) for use in treating diseases depending on the activity of a citrate transporter, wherein the compound has the general formula (I) wherein Rl is aryl, substituted aryl, st...
|
|
WO/2018/167804A1 |
The present disclosure provides solid forms of the hydrochloride salt of (5-[3-(3-Hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenyl
hexanamide (Compound-A). In particular, an amorphous form, an ethyl acetate solvate form, a methyl n-bu...
|
|
WO/2018/154519A1 |
The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compo...
|
|
WO/2018/140512A1 |
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): (I) or a pharmaceutically acceptable salt, isotopic form, stereoisomer or prodrug thereof, wherein A, B, X,...
|
|
WO/2018/140600A1 |
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I), or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein A, W, X, Y, Z, and are as d...
|
|
WO/2018/140598A1 |
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I) or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein A, B, E, L1, Ra. Rb, Rc and ...
|
|
WO/2018/140599A1 |
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I) or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein B, Z, Ra, Rb, Rc, R1, L, L1 ...
|
|
WO/2018/132073A1 |
There is provided a β-peptido sugar-copolymer having the structure of formula (I) as defined herein, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of the same. There is provided a proce...
|
|
WO/2018/115421A1 |
The present invention discloses compounds of formula (I) that are useful in the treatment of respiratory diseases of animals, especially Bovine or Swine Respiratory disease (BRD and SRD).
|
|
WO/2018/115497A1 |
The present invention relates generally to proteasome inhibiting β-lactam compounds useful for the treatment of cancer and neurodegenerative disorders. The invention also provides pharmaceutical compositions and extended release formula...
|
|
WO/2018/119362A2 |
Provided herein are compounds and methods for inhibiting histone deacetylase ("HDAC") enzymes (e.g., HDAC1, HDAC2, and HDAC3).
|
|
WO/2018/108954A1 |
Methods of making 2-(3-(fluoromethyl)azetidin-1-yl)ethan-1-ol 9, an intermediate useful for the synthesis of estrogen receptor modulating compounds are described.
|
|
WO/2018/104305A1 |
Substituted aromatic sulfonamides of formula (I) which are antagonists or negative allosteric modulators of P2X4, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a ph...
|
|
WO/2018/102419A1 |
The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
|
|
WO/2018/098208A1 |
Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.
|
|
WO/2018/091687A1 |
The disclosure provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I): (I) or an isotope labelled analog thereof, or a pharmaceutically acceptable salt thereof, wherein: each of R...
|
|
WO/2018/089402A1 |
There are described RORγ Gamma modulators of the formula (I), (I) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutic...
|
|
WO/2018/089499A1 |
The present invention provides compounds, compositions thereof, and methods of using the same.
|
|
WO/2018/083171A1 |
The invention relates to heterocyclic compounds of formula (I) as SIP modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment or alleviation of diseases or disorders mediated by an SIP receptor.
|
|
WO/2018/081343A1 |
Provided are novel compounds of Formula (I or Ia'): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with LSD1. Also provided are pharmaceutical compo...
|
|
WO/2018/071741A1 |
The invention provides sulfoxyalkyl organonitro and related compounds, compositions containing such compounds, and methods for using such compounds and compositions to treat medical disorders, such as a neurodegenerative disorder, autoim...
|
|
WO/2018/071679A1 |
The present disclosure provides certain N-Acylethanolamide derivatives, and uses relating thereto.
|
|
WO/2018/050631A1 |
The present invention relates to novel compounds of general formula (I) wherein the groups X, and R1 to R4 have the meanings given in the description and claims, process for preparing these compounds and their use as for treating, preven...
|
|
WO/2018/044963A1 |
The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical composit...
|
|
WO/2018/026763A1 |
Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutica...
|
|
WO/2017/223349A1 |
The disclosure relates to antibacterial compounds having the Formula (I), where R1, R', A, B, X, s, and o are described herein, as well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof, pharmaceutical com...
|
|
WO/2017/223243A1 |
The present invention provides compounds, compositions thereof, and methods of using the same.
|
|
WO/2017/193951A1 |
Disclosed are a class of compounds as a caspase inhibitor, and in particular the compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, and the use of the compound in treating caspase-related diseases.
|
|
WO/2017/195216A1 |
The present disclosure describes novel compounds of the general Formula (I), their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and...
|
|
WO/2017/189831A1 |
Pharmaceutical compositions of the invention comprise compounds, compositions, methods useful for the treatment of drug addiction, drug withdrawal, and diseases or conditions that involve dysregulation of glutamate homeostasis in its eti...
|
|
WO/2017/180794A1 |
Provided herein are deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams, pharmaceutical compositions thereof and methods of treating infectious disease with deuterated compounds or pharmaceutical com...
|
|
WO/2017/168438A1 |
The present invention provides an industrially advantageous process for the preparation of pure allyl protected keto derivative of formula I, an intermediate of ezetimibe. by using a novel O-allyl amide derivative of formula II. wherein ...
|
